NAD+ Four Ways: Strips vs IV vs Capsules vs Liposomal

Short answer: All four formats have a real case: IV delivers completely but requires a clinic, capsules carry the deepest human data for precursors, liposomal is a protective strategy, and sublingual strips are the most convenient with one small pilot behind them. No format has a decisive head-to-head win.

Four-way comparisons usually end with whoever published the page winning. This one grades each format on what its case actually rests on. The molecule's background lives in our NAD+ education guide.

First, the molecule's one big rule

NAD+ is a ~663-dalton, charged molecule — large and polar, a poor passive candidate for both gut absorption and mucosal absorption. Intact NAD+ does not survive digestion in any meaningful way. So the entire NAD+ market is really two markets: products delivering intact NAD+ by an alternative route (IV, sublingual, liposomal), and products delivering precursors (NMN, NR) that the body converts into NAD+ itself. Keeping that split straight is 90% of reading this category honestly — see NAD+ vs precursors.

IV: complete delivery, clinic attached

The case is airtight on delivery: intravenous infusion bypasses everything, and 100% of the dose reaches circulation by definition. It's the only format where "does it get in?" isn't a question. The practical trade-offs are equally clear — a clinic, a needle, hours of chair time, and the highest cost per dose in the category. And delivered dose is not the same as cellular outcome; controlled outcome data behind the wellness-clinic marketing remains limited. The strip-specific side of this comparison is in sublingual NAD+ vs IV.

Capsules: where the human data actually lives

Here's the pleasant surprise of the category: the deepest human evidence belongs to the humblest format — but for precursors, not intact NAD+. NR raised blood NAD+ in humans as far back as Trammell et al. 2016, and multiple NMN trials at 250–900 mg/day report similar rises. A January 2026 head-to-head (Christen et al., Nature Metabolism; n=65, 1,000 mg/day) found both NMN and NR roughly doubled blood NAD+, with no significant difference between them [published human data]. Swallowed capsules of intact NAD+ are the weakest product in this format — the gut destroys the molecule — but swallowed precursors are genuinely validated at the biomarker level. The precursor comparison continues in NMN vs NAD+.

Liposomal: a smart wrapper, waiting on its own data

Wrapping NAD+ in phospholipid spheres is a coherent strategy to protect a fragile molecule through digestion, and liposomal delivery is a mature, widely used supplement technology with established manufacturing. For NAD+ specifically, the published liposomal human data is still thin — the format borrows credibility from liposomal delivery generally. That doesn't make it wrong; it makes it promising and unproven in the specific. Buyers should ask liposomal brands to show product-specific data rather than format-general claims.

Strips: the newest route, with one small pilot

The case: route the molecule through the mouth's lining before digestion gets a vote. The most relevant data is iX Biopharma's sublingual NAD+ wafer program — a rat pharmacokinetic study reporting a twofold peak-plasma NAD+ rise within ten minutes of sublingual dosing, and a human pilot (open-label, uncontrolled, company-sponsored, nine healthy participants) reporting average whole-blood NAD+ increases of +59% at two weeks and +76% at six weeks versus baseline [published data — small, uncontrolled, sponsor-run]. That's genuinely interesting for the route — and it's why the format exists.

The InstaMed NAD+ strip (in stock, $118 per 30-strip box, on the NAD+ sublingual strips page) brings that route logic to a format people actually stick with: no water, no clinic, no swallowing a fistful of capsules. More in does sublingual NAD+ work.

So which format wins?

This is the bounded honest passage, stated once: on human evidence quality alone, swallowed precursor capsules — the cheapest, least glamorous format — currently carry the strongest data, and the strip we sell carries the least. The strip's case is route logic plus adherence, not trial results. Every format on this page is a bet of a different shape, and none has been compared head-to-head with any other.

The bottom line

Each format wins a different contest: IV wins delivery, capsules win the biomarker evidence, liposomal wins protective engineering, and strips win the contest that decides real-world results — daily consistency. The early sublingual data points in a promising direction, and the regulatory ground keeps loosening (NMN's supplement eligibility was formally reinstated by FDA in late 2025 — the rules here are actively being re-examined). Pick the format that fits your actual life, and bring a licensed provider into any NAD+ decision.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.